GSK Expects Nearly to Double Cancer Medicines in Trials Next Year
Valid market news retained in the public archive without immediate LiveCast distribution.
Related stories
Taiwan's Taiex Falls 3.0% to 44983.64
M impact | EQUITY | Oct 30, 2026, 02:03 AM UTC
SAIC Motor Shares Fall 5.9% as Q3 Profit Plunges
SAIC Motor shares fell 5.9% in early trading to a two-month low. The automaker reported third-quarter net profit on Thursday.
M impact | EQUITY | Oct 30, 2026, 02:03 AM UTC
Boston Scientific Reports Q3 Sales of $5.138 Billion, Lowers 2026 EPS Guidance
Boston Scientific reported Q3 2026 sales of $5.138 billion, up 1.5% year over year, and adjusted EPS of $0.73. It lowered full-year adjusted EPS guidance to $3.16–$3.18, citing Chi
M impact | EQUITY | Oct 30, 2026, 02:02 AM UTC
Indonesia's Benchmark Stock Index Falls 0.9% to 5,054.729
M impact | EQUITY | Oct 30, 2026, 02:01 AM UTC
Welspun Corp Q2 Net Profit Rises 3%, Plans Rs 2,280 Crore Expansion
Welspun Corp reported a 3% rise in Q2 net profit. Revenue from operations was Rs 4,644 crore. It cleared investments of up to Rs 2,280 crore across the US and Jordan; US capacity i
M impact | EQUITY | Oct 30, 2026, 02:01 AM UTC
Milky Mist Q2 Net Profit Nearly Triples as Revenue Tops ₹1,000 Crore
Milky Mist Dairy Food reported Q2 FY27 revenue from operations of ₹1,089.4 crore, up 41.6% year on year. The supplied report says net profit nearly tripled.
M impact | EQUITY | Oct 30, 2026, 02:01 AM UTC